OraSure Technologies, Inc.  

(Public, NASDAQ:OSUR)   Watch this stock  
Find more results for OSUR
6.59
-0.04 (-0.60%)
After Hours: 6.59 0.00 (0.00%)
Jul 28, 4:55PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.42 - 6.65
52 week 4.39 - 7.99
Open 6.60
Vol / Avg. 451,472.00/1.07M
Mkt cap 372.95M
P/E 35.49
Div/yield     -
EPS 0.19
Shares 55.48M
Beta 1.31
Inst. own 81%
Aug 3, 2016
Q2 2016 OraSure Technologies Inc Earnings Call - 5:00PM EDT - Add to calendar
Aug 3, 2016
Q2 2016 OraSure Technologies Inc Earnings Release - 4:00PM EDT - Add to calendar
Jul 1, 2016
OraSure Technologies Inc HCV Business Update
Jun 8, 2016
OraSure Technologies Inc at Jefferies Healthcare Conference - Webcast
May 23, 2016
OraSure Technologies Inc at UBS Global Healthcare Conference
May 17, 2016
OraSure Technologies Inc Annual Shareholders Meeting
May 4, 2016
Q1 2016 OraSure Technologies Inc Earnings Call - Webcast
May 4, 2016
Q1 2016 OraSure Technologies Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 8.41% 6.82%
Operating margin 9.28% 6.73%
EBITD margin - 11.49%
Return on average assets 5.19% 4.31%
Return on average equity 6.09% 5.13%
Employees 326 -
CDP Score - -

Address

150 WEBSTER ST
BETHLEHEM, PA 18015
United States - Map
+1-503-6416115 (Phone)
+1-610-8821830 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. Its diagnostic products include tests, such as OraQuick Rapid HIV Test, OraQuick In-Home HIV Test, OraQuick HIV Self-Test, OraQuick HCV Rapid Antibody Test, OraQuick Ebola Rapid Antigen Test, OraSure QuickFlu Rapid Flu A&B Test, OraSure Collection Device, Molecular Collection Systems, Cryosurgical Systems (Skin Lesion Removal Products), Immunoassay Tests and Reagents, Western blot HIV-1 Confirmatory Test and Q.E.D. Saliva Alcohol Test. Its products are sold in the United States and internationally to clinical laboratories and hospitals.

Officers and directors

Douglas G. Watson Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Douglas A. Michels President, Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ronald H. Spair Chief Financial Officer, Chief Operating Officer, Director
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Anthony II Zezzo II Executive Vice President - Marketing and Sales
Age: 61
Bio & Compensation  - Reuters
Mark L. Kuna Senior Vice President - Finance, Controller, Assistant Secretary
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Michael Reed Ph.D. Senior Vice President - Research and Development, Chief Scientific Officer
Bio & Compensation  - Reuters
Jack E. Jerrett Senior Vice President, General Counsel, Secretary
Age: 56
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Eamonn P. Hobbs Director
Age: 56
Bio & Compensation  - Reuters
Michael Celano Independent Director
Age: 56
Bio & Compensation  - Reuters
Ronny B. Lancaster Independent Director
Age: 63
Bio & Compensation  - Reuters